Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure

Jeppesen, 2000, Intestinal failure defined by measurements of intestinal energy and wet weight absorption, Gut, 46, 701, 10.1136/gut.46.5.701 Messing, 1991, Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome, Gastroenterology, 100, 1502, 10.1016/0016-5085(91)90645-2 O'Keefe, 2006, Short bowel syndrome and intestinal failure: consensus definitions and overview, Clin Gastroenterol Hepatol, 4, 6, 10.1016/j.cgh.2005.10.002 Buchman, 2003, AGA technical review on short bowel syndrome and intestinal transplantation, Gastroenterology, 124, 1111, 10.1016/S0016-5085(03)70064-X Wojdemann, 1998, Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs, Scand J Gastroenterol, 33, 828, 10.1080/00365529850171486 Wojdemann, 1999, Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2, J Clin Endocrinol Metab, 84, 2513, 10.1210/jcem.84.7.5840 Bremholm, 2011, The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients, Regul Pept, 168, 32, 10.1016/j.regpep.2011.03.003 Cani, 2009, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability, Gut, 58, 1091, 10.1136/gut.2008.165886 Brubaker, 1997, Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2, Am J Physiol, 272, E1050 Jeppesen, 2001, Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon, Gastroenterology, 120, 806, 10.1053/gast.2001.22555 Jeppesen, 2005, Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients, Gut, 54, 1224, 10.1136/gut.2004.061440 Jeppesen, 2011, Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome, Gut, 60, 902, 10.1136/gut.2010.218271 Jeppesen, 2009, Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life, Gastroenterol Res Pract, 2009, 425759 Jeppesen, 2009, Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function, Gastroenterol Res Pract, 2009, 616054 Crenn, 2000, Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans, Gastroenterology, 119, 1496, 10.1053/gast.2000.20227 Scolapio, 2002, Sleep patterns of cyclic parenteral nutrition, a pilot study: are there sleepless nights?, JPEN J Parenter Enteral Nutr, 26, 214, 10.1177/0148607102026003214 Thulesen, 2004, Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice, Gut, 53, 1145, 10.1136/gut.2003.035212 Compher, 2011, Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome, JPEN J Parenter Enteral Nutr, 35, 603, 10.1177/0148607111414431 Garrison, 2009, Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion, Am J Physiol Gastrointest Liver Physiol, 296, G643, 10.1152/ajpgi.90588.2008 Tavares, 2000, Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats, Am J Physiol Endocrinol Metab, 278, E134, 10.1152/ajpendo.2000.278.1.E134 Jeppeson, 2005, Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients, Gut, 54, 1224, 10.1136/gut.2004.061440 Jeppesen, 2003, Clinical significance of GLP-2 in short-bowel syndrome, J Nutr, 133, 3271, 10.1093/jn/133.11.3721